Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2023 | AAV gene therapies for hemophilia A and B

Michiel Coppens, MD, PhD, Amsterdam UMC, Amsterdam, The Netherlands, discusses adeno-associated virus (AAV) gene therapies for the treatment of hemophilia A and hemophilia B. Dr Coppens describes how these treatments have allowed many patients to discontinue prophylaxis and shares some of the differences observed between patients with hemophilia A and those with hemophilia B. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Grant/research support: Anthos, Bayer, CSL Behring/UniQure, Novo Nordisk, Roche
Lecturing/consultancy: Alexion, CSL Behring, Daiichi Sankyo, Sobi, Viatris
Member EAHAD Gene Therapy working group, ERN-EuroBloodNet